510(k) · Cleared

Cleared

BD Secondary Infusion Set

K223101510(k) TraditionalCleared May 12, 2023224-day reviewClass II21 CFR 880.5440

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Care Fusion · FPA Set, Administration, Intravascular

Cleared on May 12, 2023 as substantially equivalent to K051499 (Medegen Medical Manufacturing Services, 2005) after a 224-day review. Its family tree reaches back 2 generations to 1999.

Decided: May 12, 2023
Review: 224 days
Class: Class II
Product code: FPA
Recalls: None
Predicates: 1

Its longest line of descent runs back 2 generations to K991932 (1999). No later device cites it as a predicate yet.

By dateBy generation

Root · 2 generations backK991932 Intravascular Administration SetThe Kipp Group · 1999 · Recalled
1 generation backK051499 Intravascular Administration Set and Extension SetMedegen Medical Manufacturing Services · 2005 · Recalled
This deviceK223101 BD Secondary Infusion SetCare Fusion · 2023

View FIG. 1 as a table

Line of descent and top descendants

Generation	Number	Device	Applicant	Decided	Recalls
−2	K991932	Intravascular Administration Set	The Kipp Group	1999	2
−1	K051499	Intravascular Administration Set and Extension Set	Medegen Medical Manufacturing Services	2005	24
0 (this device)	K223101	BD Secondary Infusion Set	Care Fusion	2023	—

FIG. 1 — Lineage of K223101, 1999–2023Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in FPA? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new FPA device

#1 K243841 Sparta Infusion Set for Insulinscore 13.4 · 3 generations · no Class I recall
#2 Held for the reportin the report
#3 Held for the reportin the report

Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

Type	Number	Device	Applicant	Decided	Recalls
*	K051499	Intravascular Administration Set and Extension Set Summary page 4 …ode: FPA Trade Name: Intravascular Administration Set and Extension Set Premarket Notification #: K051499 Regulation Name: Intravascular Administration Set Classification Panel: Ge…	Medegen Medical Manufacturing Services	2005	24

Also cleared against K051499: 4 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

The line of descent spans 24 years and passes through 3 companies; a new generation was cleared every 17.9 years on median.
2 of the 2 ancestors have a recall of any class.
4 other devices also cite its predicate K051499.

How does its category compare?

All FPA devices

FPA Set, Administration, Intravascular: FDA decisions, review times, recalls and adverse event reports over 20 years. 2023, this device’s year, is highlighted.

FDA decisions per year · FPA

11in 2025

2007high 23 (2010) · low 4 (2018)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · FPA

225in 2025

2007high 340 (2023) · low 75 (2007)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · FPA

98in 2025

2007high 166 (2009) · low 1 (2021)2026

Class I (17 since 2007) Class II/III not classified

Adverse event reports per year · FPA

34,506in 2025

2007high 47,210 (2024) · low 1,499 (2007)2025

MAUDE reports naming product code FPA, not matched to any one device; reports are not rates.

View these four charts as a table

Year	Decisions	Median 510(k) review, days	Recalls (Class I)	MAUDE reports
2007	16	75	17	1,499
2008	18	89	15	1,941
2009	10	166	166	2,512
2010	23	120	58	2,537
2011	12	87	28	4,407
2012	21	96	16 (4)	4,930
2013	13	90	64	4,651
2014	22	89	24	4,695
2015	17	123	6	6,625
2016	12	195	10	8,470
2017	17	240	13	6,462
2018	4	177	4	6,574
2019	7	161	13	11,227
2020	10	327	107	9,563
2021	13	186	1	10,414
2022	14	213	9 (5)	13,393
2023	14	340	12 (4)	10,916
2024	7	244	13 (1)	47,210
2025	11	225	98 (1)	34,506
2026	5	266	10 (2)	—

What is it indicated for?

The BD Secondary Set is indicated for continuous or intermittent delivery of IV fluids, medications, including lipids, through intravascular routes of administration. The BD Secondary Set may be used with any patient population with consideration given to the procedure being performed and fluids being infused.

Indications for use as stated in the FDA summary.

https://510kreport.com/device/K223101 · printed Nov 5, 2026

Cite this page

510(k) Report. “K223101: BD Secondary Infusion Set.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K223101

Report an extraction error

Are you the manufacturer?

Record history

FDA decision record loaded May 2, 2026
Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
Lineage and recalls computed Nov 3, 2026
Page last updated Nov 3, 2026